Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about using topical finasteride or dutasteride with a testosterone and NPP cycle for hair loss. The planned treatment includes microneedling, minoxidil, pyrilutamide, and dutasteride applied topically.

A 23-year-old experienced significant hair regrowth in 3 months using a topical mixture of minoxidil 5% and finasteride 1%, with added bimatoprost. The treatment is government-subsidized, costing around $15, and the user reported no side effects.

A 29-year-old male is experiencing positive hair regrowth after 3 months using oral finasteride (1mg) and topical minoxidil (1ml twice daily), despite side effects like scalp itchiness and dandruff. He plans to continue the treatment long-term and may switch to foam minoxidil to alleviate scalp issues.

Kintor Pyrilutamide treatment, a potential hair loss treatment that may become available to the public soon. People have been experimenting with using it in topical form, with mixed results and no reported side effects.

A user experienced hair regrowth after 3 months using finasteride, both topical and oral minoxidil, 0.5mm microneedling daily, and 300mg testosterone. They reported noticeable muscle gains and no side effects while being on testosterone replacement therapy.

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.

The conversation is about a user's 3-month hair regrowth progress using finasteride, minoxidil, and a 0.5mm dermaroller, with recent addition of caffeine shampoo. Users are responding positively and inquiring about application methods.

The conversation discusses hair regrowth after 7 months of treatment, with the recent addition of tretinoin 0.05%. The treatment routine remained the same as before, except for this new addition.

The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A 19-year-old male shared his 3-month hair regrowth progress using finasteride, minoxidil, and microneedling, with noticeable improvement. He uses 1mg oral finasteride daily, 5% minoxidil foam twice a day after day 80, and microneedles with a 1.5mm derma stamp every 1-2 weeks.

The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.

The conversation discusses using tretinoin with topical minoxidil for hair regrowth, despite previous non-response to minoxidil and concerns about oral minoxidil's heart risks. The user is also on dutasteride and is considering a hair transplant if other options fail.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

The conversation discusses a user's three-month progress using topical finasteride once a day, 6% minoxidil at night, and weekly dermastamping at 1.25mm for hair loss. Commenters note the impressive results and discuss application methods and safety precautions for family members.

A humorous discussion about a newborn's hair loss, jokingly suggesting treatments like Minoxidil, finasteride, and various other hair loss remedies. Participants humorously debate extreme measures, including shaving or using a "nuclear stack" of treatments.

A user's progress with treating their hair loss, which consists of using Dutasteride, RU58841, Stemoxydine and Tretinoin 0.05% over the past three months.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

The use of tropoelastin injections and verteporfin for hair transplant recipients to help regrow donor area hairs, as well as research done on tropoelastin injections restoring elastin in scarred heart tissue and skin. There are discussions about why it is taking so long to get cosmetic mass produced tropoelastin injectables on the market.

A 33-year-old man used Minoxidil 5% and Tretinoin 0.05% for a year to address hair thinning and receding hairline, resulting in new "baby hairs" filling in thin spots. He applies Tretinoin first, lets it dry, then applies Minoxidil, and notes that consistent use is necessary to maintain results.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

A user shared their 3-month progress using oral minoxidil, finasteride, and topical minoxidil for hair loss. Another user commented on the significant improvement, hoping for similar results.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

Scientists discover SCUBE3 molecule for potential baldness cure. Mice used in research for hair growth signaling.

A user shared their positive experience with hair regrowth after three months using topical minoxidil twice daily, 1mg finasteride every morning, and microneedling every 10 days. They reported no side effects and encouraged others to consider similar treatments.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.